Technology Wire Cambodia
SEE OTHER BRANDS

Hottest science and technology news from Cambodia

Technology Wire Cambodia: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Wire Cambodia.

Press releases published on August 7, 2025

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Recent positive recommendation by the Independent Data Monitoring Committee (“IDMC”) to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven final analysis focused on disease-free survival …

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning Vonaprument Selected by EMA as One of ~20 PRIME Development Programs in the Pilot Vonaprument Has …

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates. Momentum  …

ARRAY Technologies, Inc. Reports Financial Results for the Second Quarter 2025

ARRAY Technologies, Inc. Reports Financial Results for the Second Quarter 2025

2025 Second Quarter Highlights Revenue of $362.2 million Gross Margin of 26.8% Adjusted gross margin(1) of 27.8% Net income to common shareholders of $28.5 million Adjusted EBITDA(1) of $63.6 million Net income per basic and diluted share of $0.19 Adjusted …

ESCO Reports Third Quarter Fiscal 2025 Results

ESCO Reports Third Quarter Fiscal 2025 Results

St. Louis, Aug. 07, 2025 (GLOBE NEWSWIRE) -- ESCO Technologies Inc. (NYSE: ESE) (ESCO, or the Company) today reported its operating results for the third quarter ended June 30, 2025 (Q3 2025). On July 21, 2025, the Company announced that it had completed …

Microchip Technology Announces Financial Results for First Quarter of Fiscal Year 2026

Microchip Technology Announces Financial Results for First Quarter of Fiscal Year 2026

For the quarter ended June 30, 2025 Net sales of $1.0755 billion, increased 10.8% sequentially and declined 13.4% from the year ago quarter.  The midpoint of our updated guidance provided on May 29, 2025 was net sales of $1.0575 billion. On a GAAP basis: …

Microchip Technology Announces Quarterly Cash Dividend on Common Stock of 45.5 Cents Per Share

Microchip Technology Announces Quarterly Cash Dividend on Common Stock of 45.5 Cents Per Share

CHANDLER, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today announced that its Board of Directors declared a quarterly cash …

Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference

Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference

DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a fireside chat at the …

First LLM with Infinite Context Attention is here, wiping out $1.2 billion RAG market value by allowing AI to live outside the Matrix

First LLM with Infinite Context Attention is here, wiping out $1.2 billion RAG market value by allowing AI to live outside the Matrix

SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Silicon Valley startup, iFrame™ AI, has quietly secured a nearly $20 million deal with a leading cloud provider to launch the world’s first Large Attention Model with an infinite context window - a …

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose expansions on track for data update in Q1 2026. Phase 2 …

KLEEN HY-DRO-GEN INC., Announces Launch of World’s first Zero-Emissions Hydrogen Furnace

KLEEN HY-DRO-GEN INC., Announces Launch of World’s first Zero-Emissions Hydrogen Furnace

TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- KLEEN HY-DRO-GEN INC., ( the “Company”)a Canadian clean energy company, has officially announced the public launch of KLEENHEAT™ hydrogen furnace, the world’s first and only On-Demand, Zero-Emissions home heating …

Biodesix Announces Second Quarter 2025 Results and Highlights

Biodesix Announces Second Quarter 2025 Results and Highlights

Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. …

Apyx Medical Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apyx Medical Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”) today announced that on August 4, 2025, Apyx granted a nonstatuatory stock option to purchase 100,000 shares of common stock to John …

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

-- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company's Traditional …

Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates

Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates

Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in Q2 Approximately $657 million in cash …

INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes

INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes

BOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its …

Nutanix Announces Date and Conference Call Information for Fiscal Fourth Quarter and Fiscal Year 2025 Financial Results

Nutanix Announces Date and Conference Call Information for Fiscal Fourth Quarter and Fiscal Year 2025 Financial Results

SAN JOSE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nutanix, Inc. (NASDAQ: NTNX), a leader in hybrid multicloud computing, today announced that it will report its financial results for the fiscal fourth quarter and fiscal year 2025, which ended July 31, …

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study ongoing; …

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

      Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date       Continued Progress on the Global Development Program for Atumelnant Across …

Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

BOTHELL, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions